< Back to companies
iCellate

iCellate

Solna, Sweden

iCellate is a Swedish, privately owned, stock company founded in 2011 and based in Stockholm. iCellate develops products in the field of cancer research and detection, more specifically circulating tumor cells (CTC). iCellate® is based on research from the Karolinska Institute in collaboration with the Karolinska University Hospital and the Royal Institute of Technology in Stockholm. The company was inducted in the respected business incubator Stockholm Innovation and Growth (STING) in August 2011 and is supported by the Karolinska Institute’s Innovation Office. The company has received competitive business development grants from the Swedish Governmental Agency for Innovation Systems – VINNOVA, Uppsala Bio, Eurostars and the Swedish Incubators and Science Parks – SISP.

Only accessible to MedStartr community members. Join now

Company Info

Founded
2011
Website
icellate.com/

Categories

Cancer

Disease Areas

Technologies

Diagnostics & Lab TechBiomarker AnalysisLiquid BiopsyMolecular Diagnostics
Only accessible to MedStartr community members. Join now

What do you think of iCellate?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Innovation

Clinical Benefit

Feasibility

Scalability

Only accessible to MedStartr community members. Join now